Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex

Current Pharmaceutical Design

Volumn 12, Issue 19, 2006, Pages 2409-2424

  Oliveira, Jaim S ^a,b   de Sousa, Eduardo H S ^c   de Souza, Osmar N ^a   Moreira, Ícaro S ^c   Santos, Diógenes S ^a   Basso, Luiz A ^a,b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Enoyl reductase; InhA; Inhibitors; Inorganic complex; Isoniazid; Molecular modeling; Mycolic acids; Tuberculosis

Indexed keywords

1 ISONICOTINYL 2 NONAOYL HYDRAZINE; AMIKACIN; AMINOSALICYLIC ACID; ANTIMYCOBACTERIAL AGENT; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; CYCLOSPORIN; ENOYL COENZYME A HYDRATASE; ETHAMBUTOL; ETHIONAMIDE; FERRIC PENTACYANO(ISONIAZID); INORGANIC COMPOUND; ISONIAZID; ISONIAZID DERIVATIVE; KANAMYCIN; KATG PROTEIN; MYCOLIC ACID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; BACTERIAL CELL WALL; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BINDING KINETICS; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; CRYSTAL STRUCTURE; DISEASE PREDISPOSITION; DISSOCIATION CONSTANT; DRUG DESIGN; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; FATTY ACID SYNTHESIS; GENE TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; MOLECULAR MODEL; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; STRUCTURAL GENE; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG DESIGN; HUMANS; ISONIAZID; KINETICS; MYCOBACTERIUM TUBERCULOSIS; NAD; OXIDOREDUCTASES; TUBERCULOSIS;

EID: 33745745598     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777698927     Document Type: Review

References (94)

1. Raviglione MC. The TB epidemic from 1992 to 2002. Tuberculosis 2003; 83: 4-14.
2. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-21,
3. Morens DM, Folkers, GK, Fauci, AS. The challenge of emerging and re-emerging infectious diseases. Nature 2004; 430: 242-248.
4. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999; 282: 677-86.
5. Espinal MA. The global situation of MDR-TB. Tuberculosis 2003; 83: 44-51.
6. World Health Organization. Anti-tuberculosis drug resistance in the world: Third Global Report. 2004.
7. Nunn P. WHO Global TB Programme, Tuberculosis Research and Surveillance Unit of the WHO Global TB Programme; Press Release WHO/74(www.who.int/ gtb/press/who74.htm), 1997.
8. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004; 10: 1111-16.
9. McKinney JD, Jacobs WRJr., Bloom BR. In: Krause RM Ed, Emerging Infections. New York, Academic Press. 1998; 51-146.
10. Pablos-Méndez A, Gowda DK, Frieden TR. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull. World Health Organ 2002: 80: 489-95.
11. Duncan K. Progress in TB drug development and what is still needed. Tuberculosis 2003; 83: 201-7.
12. Hingley-Wilson SM, Sambandamurthy VK, Jacobs WRJr. Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis. Nat Immunol 2003; 4: 949-55.
13. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis 2004; 84: 29-44.
14. Schatz A, Bugie E, Waksman SA Streptomycin, a substrate exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc Soc Exp Biol Med 1944; 55: 66.
15. Middlebrook G. Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro. Am Rev Tuberc 1952; 65: 765-7.
16. Kushner S, Dalalian H, Sanjurjo JL, Bach FL, Safir SR, Smith VK Jr, et al. Experimental chemotherapy of tuberculosis. The synthesis of pyrazinamides and related compounds. J Am Chem Soc 1952; 74: 3617-21.
17. Basso LA, Blanchard JS. Resistance to antitubercular drugs. Adv Exp Med Biol 1998; 456:115-44.
18. Mitchison DA The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-25.
19. Heifets LB. Antimycobacterial drugs. Semin Respir Infect 1994; 9: 84-103
20. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998, 79: 3-29.
21. Glickman MS, Jacobs WRJr. Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell 2001; 104: 477-85.
22. Schroeder EK, de Souza ON, Santos DS, Blanchard JS, Basso LA. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr Pharm Biotechnol 2002; 3: 197-225.
23. Dutt AK, Stead W. The treatment of tuberculosis. Dis. Month 1994; 43: 247-74.
24. Blanchard JS. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu Rev Biochem 1996; 65: 215-39.
25. Banerjee A, Dubnau E, Quémard A, Balasubramanian V, Um KS, Wilson T, et al. InhA, a Gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-30.
26. Quémard A, Sacchettini JC, Dessen A, Vilchèze C, Bittman R, Jacobs WR Jr, et al. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 1995; 34: 8235-41.
27. Vilchèze C, Morbidoni HR, Weisbrod TR, Iwamoto H, Kuo M, Sacchettini JC, et al. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J Bacteriol 2000; 182: 4059-67.
28. Larsen MH, Vilchèze C, Kremer L, Besra GS, Parsons L, Salfinger M, et al. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol 2002; 46: 453-66.
29. Kremer L, Dover LG, Morbidoni HR, Vilchèze C, Maughan WN, Baulard A, et al. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J Biol Chem 2003; 278: 20547-54.
30. Basso LA, Zheng R, Musser JM, Jacobs WRJr, Blanchard JS. Mechanism of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J Infect Dis 1998; 178: 769-75.
31. Dessen A, Quémard A, Blanchard JS, Jacobs WRJr, Sacchettini JC. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 1995; 267: 1638-41.
32. Schroeder EK, Basso LA, Santos DS, de Souza ON. Molecular dynamics simulation studies of the wild-type, I21V and I16T mutants of isoniazid resistant Mycobacterium tuberculosis enoyl reductase (InhA) in complex with NADH: towards the understanding of NADH-InhA different affinities. Biophys J 2005 (accepted for publication, Epud ahead of print, PMID: 15908576).
33. Heym B, Alzari PM, Honoré N, Cole ST. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 1995; 15: 235-45.
34. Ramaswamy SV, Reich R, Dou S-J, Jasperse L, Pan X, Wanger A, et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 1241-50.
35. Yu S, Girotto S, Lee C, Magliozzo RS. Reduced affinity for isoniazid in the S315T mutant of Mycobacterium tuberculosis KatG is a key factor in antibiotic resistance. J Biol Chem 278: 14769-75.
36. Johnsson K, Schultz PG. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J AmChem Soc 1994; 116: 7425-6.
37. Johnsson K, King DS, Schultz PG. Studies on the mechanism of action of isomazid and ethionamide in the chemotherapy of tuberculosis. J Am Chem Soc 1995; 117: 5009-10.
38. Basso LA, Zheng I, Blanchard JS. Kinetics of inactivation of WT and C243S mutant of Mycobacterium tuberculosis enoyl reductase by activated isoniazid. J Am Chem Soc 1996; 118: 11301-2.
39. Zabinski RF, Blanchard JS. The requirement for manganese and oxygen in the isoniazid-dependent inactgivation of Mycobacterium tuberculosis enoyl reductase. J Am Chem Soc 1997; 119: 2331-2.
40. Rozwarski DA, Grant GA, Barton DHR, Jacobs WRJr, Sacchettini JC. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998; 279: 98-102.
41. Lei B, Wei C-J, Tu S-C. Action mechanism of antitubercular isoniazid. J Biol Chem 2000; 275: 2520-6.
42. Rawat R, Whitty A, Tonge PJ. The isonizid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc Natl Acad Sci USA 2003; 100: 13881-6.
43. Johnsson K, Froland WA, Schultz PG. Overexpression, purification, and characterization of the catalase-peroxidase KatG from Mycobacterium tuberculosis. J Biol Chem 1997; 272: 2834-40.
44. Chouchane S, Lippai I, Magliozzo RS. Catalase-peroxidase (Mycobacterium tuberculosis KatG) catalysis and isoniazid activation. Biochemistry 2000; 39: 9975-83.
45. Chouchane S, Girotto S, Yu S, Magliozzo RS. Identification and characterization of tyrosyl radical formation in Mycobacterium tuberculosis catalase-peroxidase (KatG). J Biol Chem 2002; 277: 42633-8.
46. Zhao X, Girotto S, Yu S, Magliozzo RS. Evidence for radical formation at Tyr-353 in Mycobacterium tuberculosis catalase-peroxidase (KatG). J Biol Chem 2004; 279: 7606-12.
47. Bertrand T, Eady NAJ, Jones JN, Nagy JJM, Jamart-Grégoire B, Raven EL, et al. Crystal structure of Mycobacterium tuberculosis catalase-peroxidase. J Biol Chem 2004; 279: 38991-9
48. Pierattelli R, Banci L, Eady NAJ, Bodiguel J, Jones JN, Moody PCE, et al. Enzyme-catalyzed mechanism of isoniazid activation in Class I and Class III peroxidases. J Biol Chem 2004; 279: 39000-9.
49. Magliozzo RS, Marcinkeviciene JA. The role of Mn(II)-peroxidase activity of mycobacterial catalase-peroxidase in activation of the antibiotic isoniazid. J Biol Chem 1997; 272: 8867-70.
50. Wilming M, Johnsson K. Spontaneous formation of the bioactive form of the tuberculosis dmg isoniazid. Angew Chem Int Ed 1999; 38: 2588-90.
51. III-pyrophosphate in the presence of NADH produces the inhibition of the enoyl-ACP reductase InhA from Mycobacterium tuberculosis. C R Acad Sci Paris, Série IIc, Chimie 2001; 4: 35-40.
52. Scior T, Morales IM, Eisele SJG, Domeyer D, Laufer S. Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis - a review. Arch Pharm Pharm Med Chem 2002; 11: 511-25.
53. Mohamad S, Ibrahim P, Sadikun A. Susceptibility of Mycobacterium tuberculosis to isoniazid and its derivative, 1-isonicotinyl-2-nonanoyl hydrazine: investigation at cellular level. Tuberculosis 2004; 84: 56-62.
54. Hearn MJ, Cynamon MH. Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base. J Antimicrob Chemother 2004; 53: 185-191.
55. Walsh C. Where will new antibiotics come from? Nature Rev Microbiol 2003; 1: 65-70.
56. Oliveira JS, Sousa EHS, Basso LA, Palaci M, Dietze R, Santos DS, et al. An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis. Chem Commun 2004; 3: 312-3.
57. DeBarber A, Mdluli K, Bosman M, Bekker L-G, Barry CEIII. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000; 97: 9677-82.
58. Moreira IS, Franco DG. Ruthenium(II) and iron(II) complexes of 4,4-dithiodipyridine. Synthesis, characterization, and reactivity studies. Inorg. Chem. 1994; 33: 1607-13
59. Moreira IS, Lima JB, Franco DW. Manifestation of sulfur-to-sulfur interaction in complexes of iron, ruthenium and osmium. Coord Chem Rev. 2000; 196: 197-217.
60. Morrison JF, Walsh CT. The behaviour and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 1988; 61: 201-301.
61. Liu W, Rogers CJ, Fisher AJ, Toney MD. Aminophosphonate inhibitors of dialkylglycine decarboxylase: structural basis for slow binding inhibition. Biochemistry 2002; 41:12320-8.
62. Morrison JF, The slow-binding and slow, tight-binding inhibition on enzyme-catalysed reactions. Trends Biochem Sci 1982, 9: 102-105.
63. Stone SR, Hermans JM. Inhibitory mechanism of serpins. Interaction of thrombin with antithrombin and protease nexin 1. Biochemistry 1995; 34: 5164-72.
64. Erion MD, Walsh CT. 1-Aminocyclopropanephosphonate: Time-dependent inactivation of 1-aminocyclopropanecarboxylate deaminase and Bacillus stearothermophilus alanine racemase by slow dissociation behaviour. Biochemistry 1987; 26: 3417-25.
65. Shapiro R, Riordan JF. Inhibition of angiotensin converting enzyme: Dependence on chloride. Biochemistry 1984; 23: 5334-40.
66. Schoss JV. Significance of slow-binding enzyme inhibition and its relationship to reaction-intermediate analogues. Acc Chem Res 1988; 21: 348-53.
67. Sotriffer CA, Flader W, Winger RH, Rode BM, Liedl KR, Varga JM. Automated docking of ligands to antibodies: methods and applications. Methods: A Companion to Methods Enzymol 2000a; 20: 280-91.
68. Thomsen R. Flexible ligand docking using evolutionary algorithms: investigating the effects of variation operators and local search hybrids. Biosystems 2003; 72: 57-73.
69. Stahl M, Rarey M. Detailed analysis of scoring functions for virtual screening. J Med Chem 2001; 29: 1035-42.
70. Sotriffer CA, Ni HH, McCammon JA. Active site binding modes of HIV-1 integrase inhibitors. J. Med. Chem 2000; 43: 4109-17.
71. Brooijmans N, Kuntz ID. Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct 2003; 32: 335-73.
72. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian Genetic Algorithm and and empirical binding free energy function. J Comput Chem 1998; 19:1639-62.
73. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, et al. Gaussian 98, Revision A.6, Gaussian, Inc.: Pittsburgh, PA, 1998.
74. Bayly CI, Cieplak P, Cornell WD, Kollman PA. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges - the RESP model. J Phys Chem 1993; 97: 10269-80.
75. Case DA, Pearlman DA, Caldwell JW, Cheatham I, Ross WS, Simmerling C, et al. AMBER, 5.0; University of California: San Francisco, 1997.
76. + and a C16 fatty acyl substrate. J Biol Chem 1999; 274: 15582-89.
77. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res 2000; 28: 235-42.
78. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE, Ferguson DM, et al. AMBER 4.1, University of California, San Francisco, 1995.
79. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
80. Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson WJ, et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 2002; 184: 5479-90.
81. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409: 1007-11.
82. Garnier T, Eiglmeier K, Camus J-C, Medina N, Mansoor H, Pryor M, et al. The complete genome sequence of Mycobacterium bovis. Proc Natl Acad Sci USA 2003; 100: 7877-82
83. Terwilliger TC, Park MS, Waldo GS, Berendzen J, Hung L-W, Kim C-Y, et al. The TB structural genomics consortium: a resource for mycobacterium tuberculosis biology. Tuberculosis 2003; 83 223-49.
84. Teague SJ, Davis, AM, Leeson PD, Oprea T. The design of lead-like combinatorial libraries. Angew Chem Int Ed Engl 1999; 38: 3743-3748.
85. Zhang CX, Lippard SJ. New metal complexes as potential therapeutics. Curr Opin Chem Biol 2003; 7:481-9.
86. Sanchez-Delgado RA, Anzellotti A. Metal complexes as chemotherapeutic agents against tropical diseases: trypanosomiasis, malaria and leishmaniasis. Mini Rev Med Chem. 2004; 4: 23-30.
87. Sanchez-Delgado RA, Navarro M, Perez H, Urbina JA. Toward a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium- and rhodium-chloroquine complexes. J Med Chem. 1996; 39:1095-99.
88. Navarro M, Perez H, Sanchez-Delgado RA. Toward a novel metal-based chemotherapy against tropical diseases. 3. Synthesis and antimalarial activity in vitro and in vivo of the new gold-chloroquine complex [Au(PPh3)(CQ)]PF6. J Med Chem. 1997; 40:1937-9.
89. Navarro M, Vasquez F, Sanchez-Delgado RA, Perez H, Sinou V, Schrevel J. Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes. J Med Chem. 2004; 47:5204-9.
90. Sandbhor U, Padhye S, Billington D, Rathbone D, Franzblau S, Anson CE, et al. Metal complexes of carboxamidrazone analogs as antitubercular agents. 1. Synthesis, X-ray crystal-structures, spectroscopic properties and antimycobacterial activity against Mycobacterium tuberculosis H37Rv. J Inorg Biochem 2002; 90: 127-36.
91. Dagani R. The bio side of organometallics. C&EN 2002; 80: 23-29.
92. Barry CE 3rd, Boshoff HI, Dowd CS. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr Pharm Des 2004; 10(26): 3239-62.
93. Duncan K. Identification and validation of novel drug targets in tuberculosis. Curr Pharm Des 2004; 10(26): 3185-94.
94. Mitchison DA, Coates AR. Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs. Curr Pharm Des 2004; 10(26): 3285-95.